Evidence map›Paper›PMID 37081189›Full record

ReviewBritish journal of cancer2023

HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.

Vincenzo Formica, Silvia Riondino, Cristina Morelli, Simona Guerriero, Federica D'Amore, Antonio Di Grazia, Giovanna Del Vecchio Blanco, Giuseppe Sica, Hendrik-Tobias Arkenau, Giovanni Monteleone and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Vincenzo FormicaMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy. v.formica1@gmail.com.ORCID http://orcid.org/0000-0002-5380-3144
Silvia RiondinoMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
Cristina MorelliMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
Simona GuerrieroMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
Federica D'AmoreMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
Antonio Di GraziaGastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Giovanna Del Vecchio BlancoGastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Giuseppe SicaDepartment of Surgery, University of Rome Tor Vergata, Rome, Italy.
Hendrik-Tobias ArkenauDrug Development Unit, Sarah Cannon Research Institute UK, London, UK.
Giovanni MonteleoneGastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Mario RoselliMedical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
University of Rome Tor Vergata · ITSarah Cannon Research Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Not all aspects of the disruption of iron homeostasis in cancer have been fully elucidated. Iron accumulation in cancer cells is frequent for many solid tumours, and this is often accompanied by the contemporary rise of two key iron regulators, HIF2α and Hepcidin. This scenario is different from what happens under physiological conditions, where Hepcidin parallels systemic iron concentrations while HIF2α levels are inversely associated to Hepcidin. The present review highlights the increasing body of evidence for the pro-tumoral effect of HIF2α and Hepcidin, discusses the possible imbalance in HIF2α, Hepcidin and iron homeostasis during cancer, and explores therapeutic options relying on these pathways as anticancer strategies.

Indexed as

HepcidinsNeoplasmsHumansIronSignal TransductionHepcidinsIron

Identifiers

PMID37081189
PMCPMC10338631
OpenAlexW4366496091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.